Skip to main content

Month: May 2024

Fate Therapeutics Announces First Lupus Patient Treated in Phase 1 Autoimmunity Study of Off-the-shelf FT819 CAR T-cell Program

Pre-treatment Sample of Patient’s Blood Showed Rapid and Potent Depletion of CD19+ B Cells in Ex Vivo Cytotoxicity Assay with FT819 Translational Data from FT819 Phase 1 B Cell Malignancies Study Support Key Therapeutic Mechanisms of Activity for B Cell-mediated Autoimmune Diseases Initial Clinical Observations of FT522 CAR NK Cell Program in Phase 1 B Cell Lymphoma Study Show Rapid, Deep, and Sustained B Cell Depletion and Enhanced Persistence in the Periphery SAN DIEGO, May 09, 2024 (GLOBE NEWSWIRE) — Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune diseases, today announced that the first patient with systemic lupus erythematosus (SLE)...

Continue reading

Odysight.ai Receives a Purchase Order from Tel Aviv University and the Israel Ministry of Defense for a Bespoke System Based on Its Proprietary Visual Sensors

OMER, Israel, May 09, 2024 (GLOBE NEWSWIRE) — Odysight.ai Inc. (OTCQB: ODYS), a leading provider of visual based predictive maintenance (PdM) and condition-based monitoring (CBM) solutions, is pleased to announce the receipt of a purchase order from Tel Aviv University for a research and development project of the Israeli Ministry of Defense for a bespoke system based on its proprietary visual sensors. Odysight believes the purchase order showcases the wide variety of applications for its visual know-how and proven expertise. Odysight.ai’s unique system provides a state-of-the-art solution, using advanced visual and processing capabilities, minimizing weight and size to meet challenging operating requirements. Odysight.ai’s unique technological capabilities and flexibility allow the rapid development of solutions to critical client...

Continue reading

SRM Expands with New Order that Helps Theme Park Guests Stay Cool in the Summertime Heat

JUPITER, FL, May 09, 2024 (GLOBE NEWSWIRE) — SRM Entertainment, Inc., (Nasdaq: SRM) (the “Company” or “SRM”) is pleased to announce a new regional theme park product order for our exclusive, colorful misting fans. The “fan favorite” is great to help beat the summer heat while your enjoying a fun day at one of America’s premier amusement parks. The 30,000+ unit order increases SRM’s expansion efforts with one of the largest regional amusement-resort operators in the world that welcomes approximately 28 million guests annually to parks located throughout the US. “SRM is striving to build relationships with premier entertainment destinations. Summertime is fun time for millions of people and we’re looking forward to helping them stay cool.” stated SRM’s CEO Rich Miller. About SRM Entertainment, Inc. SRM Entertainment designs, develops,...

Continue reading

NewLake Capital Partners Reports First Quarter 2024 Financial Results

First Quarter 2024 Revenue Totaled $12.6 Million, an increase of 10.4% Year-Over-Year First Quarter 2024 Net Income Attributable to Common Stockholders Totaled $6.9 Million, Funds from Operations Totaled $10.6 Million, and Adjusted Funds from Operations Totaled $11.0 Million Conference Call and Webcast Scheduled for May 9, 2024, at 11 a.m. Eastern Time NEW CANAAN, Conn., May 09, 2024 (GLOBE NEWSWIRE) — NewLake Capital Partners, Inc. (OCTQX: NLCP) (the “Company” or “NewLake”), a leading provider of real estate capital to state-licensed cannabis operators, today announced its financial results for the first quarter ended March 31, 2024. Anthony Coniglio, President and Chief Executive Officer, said, “We are pleased with the performance of our portfolio and financial results during the first quarter of 2024. Our growth in revenue and...

Continue reading

CRISPR Therapeutics to Present at the Bank of America Securities Health Care Conference

ZUG, Switzerland and BOSTON, May 09, 2024 (GLOBE NEWSWIRE) — CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that members of its senior management team will present at the Bank of America Securities Health Care Conference on Wednesday, May 15, 2024, at 12:20 p.m. ET. A live webcast of the fireside chat will be available on the “Events & Presentations” page in the Investors section of the Company’s website at https://crisprtx.gcs-web.com/events. A replay of the webcast will be archived on the Company’s website for 14 days following the presentation. About CRISPR TherapeuticsSince its inception over a decade ago, CRISPR Therapeutics has transformed from a research-stage company advancing programs...

Continue reading

Selectis Health Enters Definitive Purchase and Sale Agreement for Archway Transitional Care Center in Georgia

– Archway Nursing Facility and Related Property to be Sold for $6.75 Million – Greenwood Village, Colorado, May 09, 2024 (GLOBE NEWSWIRE) — Selectis Health, Inc. (OTC: GBCS) (“Selectis” or the “Company”) announced that its wholly-owned subsidiary, Goodwill Hunting, LLC (the “Seller”), has executed and delivered a definitive Purchase and Sale Agreement (the “PSA”) to sell certain real property located in Macon, Bibb County, Georgia, including the skilled nursing facility known as Archway Transitional Care Center1 (collectively, “the Archway Property”). Pursuant to the PSA, Bibb County Holdings II, LLC (the “Purchaser”) has agreed to purchase the Archway Property for $6.75 million, subject to certain prorations, holdbacks, and adjustments customary in transactions of this nature. The Seller and...

Continue reading

Adeia Renews Media IP License Agreement with Panasonic Entertainment & Communication Co., Ltd.

SAN JOSE, Calif., May 09, 2024 (GLOBE NEWSWIRE) — Adeia Inc. (Nasdaq: ADEA), the company whose patented innovations shape the way the world explores and experiences entertainment, today announced that Panasonic Entertainment & Communication Co., Ltd. (“Panasonic”), a global provider of services and products, has agreed to a multi-year renewal of its license for Adeia’s media intellectual property (IP) portfolio. As a leading manufacturer of smart and connected TVs and a wide range of consumer electronics, Panasonic has played an iconic role in offering customers around the world access to innovative digital and entertainment technologies. “Panasonic is a touchstone brand for an extensive lineup of consumer electronics, including smart and connected TVs,” said Dr. Mark Kokes, Adeia’s chief licensing...

Continue reading

Dorel Industries Will Hold a Conference Call to Discuss Its First Quarter Results

MONTREAL, May 09, 2024 (GLOBE NEWSWIRE) — Dorel Industries, Inc. (TSX: DII.B, DII.A)CONFERENCE CALL:OPEN TO: Analysts, investors and all interested partiesDATE: Friday, May 10, 2024TIME: 1:00 PM Eastern TimeCALL: 1-800-319-4610   THE PRESS RELEASE WILL BE PUBLISHED BEFORE MARKETS OPEN THE SAME DAY THROUGH GLOBENEWSWIRE. Please dial in 15 minutes before the conference begins. If you are unable to call in at this time, you may access a recording of the meeting by calling 1-800-319-6413 and entering the passcode 0766 on your phone. This recording will be available on Friday, May 10, 2024 as of 4:30 PM until 11:59 PM on Friday, May 17, 2024. MEDIA WISHING TO QUOTE AN ANALYST SHOULD CONTACT THE ANALYST PERSONALLY FOR PERMISSION. NOTE TO FIRST-TIME ANALYSTS: Please contact Rick Leckner at Saint Victor Investments...

Continue reading

Join Nexalin Technology’s Exclusive Live Investor Webinar and Q&A Session on May 23

HOUSTON, May 09, 2024 (GLOBE NEWSWIRE) — Nexalin Technology, Inc. (the “Company” or “Nexalin”) (Nasdaq: NXL; NXLIW) is pleased to invite investors to a webinar on May 23, 2024, at 4:15 p.m. ET. The exclusive event, hosted by RedChip Companies, will feature Nexalin CEO Mark White, who will share insight into the Company’s growing clinical data supporting its non-invasive, frequency-based deep brain stimulation device, as well as progress on its new Gen-3 HALO™ Clarity & Virtual Clinic model. A live Q&A session with White will follow the presentation. To register for the free webinar, please visit: https://redchip.zoom.us/webinar/register/WN_kFIw9RFmQnqrPAX03eC20w#/registration Questions can be pre-submitted to NXL@redchip.com or online during the live event. About Nexalin Technology, Inc. Nexalin designs and develops...

Continue reading

Antelope Enterprise Announces Second Half and Fiscal Year End 2023 Earnings Conference Call

The rescheduled Earnings Conference Call is to be Held on Friday, May 10, 2024 at 5:00 am (Pacific) / 8:00 am (Eastern) / 8:00 pm (Beijing / Hong Kong) NEW YORK, May 09, 2024 (GLOBE NEWSWIRE) — Antelope Enterprise Holdings Limited (NASDAQ Capital Market: AEHL) (“Antelope Enterprise”, “AEHL” or the “Company”), which operates KylinCloud, a livestreaming ecommerce business in China with access to 800,000+ hosts and influencers, today announced that it will conduct a conference call at 8:00 am Eastern Time on Friday, May 10, 2024, to discuss its second half and full year financial results for its fiscal year ended December 31, 2023. The Second Half and Fiscal Year End 2023 Earnings Press Release will be available prior to the Company’s Earnings Conference Call at: https://www.nasdaq.com/market-activity/stocks/aehl/press-releases. To...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.